Stocktoria
CorMedix Inc. CRMD
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2010-03-25
CorMedix Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 88.5% | 92.7% | — | 94.3% | 22.0% |
| Operating margin | 48.2% | -51.4% | — | -46819.9% | -15417.5% |
| Net margin | 52.3% | -41.2% | — | -45409.9% | -14774.7% |
| FCF margin | 55.4% | -116.7% | — | -37573.5% | -11826.2% |
| Return on assets | 19.7% | -15.1% | -56.5% | -47.9% | -40.9% |
| Return on equity | 40.2% | -21.2% | -66.1% | -53.9% | -44.9% |
| Current ratio | 2.11 | 3.39 | 6.97 | 9.44 | 12.44 |
| Revenue growth | 617.0% | — | — | -65.7% | -20.2% |
Source: SEC EDGAR filings · CIK 0001410098 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.